Fastep's COVID-19 antigen pen test clears the FDA for over-the-counter home use

On June 5, 2026, the FDA cleared the Fastep COVID-19 Antigen Pen Home Test and Fastep COVID-19 Antigen Pen Test from Assure Tech., LLC through the 510(k) pathway, recording the decision as clearance number K260754. The submission was a Traditional 510(k) received on March 9, 2026 and found Substantially Equivalent — a turnaround of well under three months. The device sits in the Microbiology advisory panel under product code QYT, regulation 866.3984, as a Class II device.

The headline detail for a consumer-tech audience is the word home. One of the two cleared configurations is explicitly an over-the-counter home test, which places it in a regulatory category built for unsupervised lay use rather than a clinical laboratory. The FDA's classification record for QYT defines the generic device type, and the intended use, in a single verbatim sentence.

"For the rapid, qualitative detection of SARS-CoV-2 virus nucleocapsid protein antigen in individuals 2 years and older."— FDA Product Classification, product code QYT, source

Three constraints are encoded in that sentence, and each shapes what Assure Tech can claim. The test is qualitative — it returns a positive or negative result, not a viral load. It targets the nucleocapsid protein antigen, the specific SARS-CoV-2 protein these rapid tests detect. And it is validated for individuals 2 years and older, a population boundary that matters for an OTC product a parent might use on a child.

Why a traditional 510(k) for a consumer test is notable

For much of the pandemic, rapid antigen tests reached the market through Emergency Use Authorizations, a pathway distinct from the standard 510(k) process. The existence of a settled product code — QYT, 'Over-The-Counter Covid-19 Antigen Test' — and a Traditional 510(k) clearance under it signals that the category has matured into routine premarket review. COVID-19 antigen self-tests are now cleared the way other established Class II diagnostics are: against a defined regulation, with a named predicate, on the strength of substantial-equivalence data.

That maturation is itself the story for anyone tracking the consumer-diagnostics landscape. A device cleared under a stable product code inherits a known set of special controls and a predictable review path, which lowers the barrier for follow-on entrants and incremental form-factor changes. The 'pen' format Assure Tech cleared is a packaging and usability variation on the familiar lateral-flow antigen test — the kind of iteration the system is now built to process quickly, as the sub-three-month review here demonstrates.

The OTC distinction does real work

The split between the two cleared configurations — a home test and a (presumably point-of-care or professional) pen test — is not cosmetic. An over-the-counter clearance requires the FDA to be satisfied that a layperson can run the test and interpret the result correctly without professional supervision, which typically demands human-factors and usability data that a professional-use clearance does not. Clearing both configurations under a single 510(k) suggests Assure Tech demonstrated that the same chemistry performs acceptably across both use settings.

For the consumer who buys a box off a pharmacy shelf, the practical meaning is straightforward: the test is authorized for self-use, returns a yes/no answer on SARS-CoV-2 antigen, and is validated down to age two. For the strategist watching the diagnostics market, the meaning is that respiratory self-testing has settled into a normalized, repeatable clearance lane — and that incumbents and new entrants alike can now compete on usability, cost, and distribution rather than on regulatory novelty.

What the constraints mean on the box

It is worth dwelling on the three constraints the QYT definition encodes, because each one maps to a real limit a consumer should understand. 'Qualitative' means the test answers a yes-or-no question — is SARS-CoV-2 antigen present above the test's threshold — and nothing more. It does not quantify how much virus is present, and a faint line is not a measure of severity. 'Nucleocapsid protein antigen' identifies the molecular target: these rapid tests look for a specific structural protein of the virus, which is why they can return a result in minutes without the amplification step a molecular PCR test requires. And the 'individuals 2 years and older' boundary reflects the population in which the device type's performance is established; it is the kind of detail that governs whether an OTC label can responsibly be used on a toddler.

Those constraints also explain the well-known tradeoffs of antigen self-testing. Because the method detects protein antigen directly rather than amplifying genetic material, it is fast and cheap but generally less sensitive than a laboratory molecular test, particularly early in an infection or at low viral loads. None of that is a defect specific to Fastep; it is inherent to the antigen category the QYT code defines. A clearance under QYT therefore tells the buyer what kind of test they are getting — a rapid screen, not a definitive molecular diagnosis — before they ever read the insert.

The landscape view: a normalized category

Zooming out, the most durable signal in this clearance is structural rather than product-specific. The presence of a stable product code, a defined regulation, and a routine Traditional 510(k) clearance means SARS-CoV-2 self-testing has fully exited the emergency-authorization era and entered the same predictable lifecycle as pregnancy tests, glucose meters, and other established OTC diagnostics. For the consumer-diagnostics landscape, that normalization lowers barriers for new entrants and form-factor variants, shifts competition toward usability and price, and turns what was once a scramble for emergency authorization into a repeatable, plannable regulatory path.

What the record fixes

The openFDA entry establishes, verbatim, that this is Assure Tech's device, cleared June 5, 2026 as K260754, determined Substantially Equivalent, classified as Class II under product code QYT in the Microbiology panel. The classification record supplies the intended-use sentence quoted above. The full 510(k) summary — not yet reflected in the API entry beyond 'Summary' — will name the predicate and the specific clinical-agreement performance figures (sensitivity and specificity) on which the clearance rests.

Until then, the durable facts are the ones the record states plainly: a rapid, qualitative SARS-CoV-2 antigen test, cleared for over-the-counter home use in people two and older, processed through the ordinary 510(k) machinery in under a quarter. That last point — the speed and routineness — is the quiet signal that consumer COVID testing has graduated from emergency improvisation to standing infrastructure.